Results 41 to 50 of about 6,232 (244)

microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy

open access: yesFrontiers in Immunology, 2020
IgA nephropathy (IgAN) is the most common primary glomerular disease. The characteristic pathology involves immune complexes formed by the deposition of IgA1 and underglycosylated IgA1 aggregates in the mesangial area, which may be accompanied by the ...
Chan Liu   +5 more
doaj   +1 more source

Prospects for Treatment of Idiopathic Pulmonary Fibrosis

open access: yesАрхивъ внутренней медицины, 2022
Idiopathic pulmonary fibrosis (IPF) is a severe, progressive lung disease of unknown etiology with an average worldwide prevalence of 15 per 100,000. According to the etiology, IPF is classified into sporadic, syndromic, and familial cases.
R. N. Mustafin
doaj   +1 more source

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression [PDF]

open access: yes, 2016
MicroRNAs (miRNAs) are small RNA molecules that affect cellular processes by controlling gene expression. Recent studies have shown that hypoxia downregulates Drosha and Dicer, key enzymes in miRNA biogenesis, causing a decreased pool of miRNAs in cancer,
Armaiz-Pena,   +18 more
core   +2 more sources

Molecular genetics of idiopathic pulmonary fibrosis

open access: yesВавиловский журнал генетики и селекции, 2022
Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung disease with a prevalence of 2 to 29 per 100,000 of the world’s population. Aging is a significant risk factor for IPF, and the mechanisms of aging (telomere depletion, genomic
R. N. Mustafin
doaj   +1 more source

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab [PDF]

open access: yes, 2016
Purpose: We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients.
Afonyushkin   +44 more
core   +1 more source

Data from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death

open access: yes, 2023
<div>Abstract<p>MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non–small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP).
Guido Kroemer   +15 more
openaire   +1 more source

Differential expression of microRNAs in GH-secreting pituitary adenomas [PDF]

open access: yes, 2010
Background The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs ...
Zhi-Gang Mao   +7 more
core   +1 more source

Extracellular vesicle miRNAs in breast milk of obese mothers

open access: yesFrontiers in Nutrition, 2022
BackgroundBreast milk has abundant extracellular vesicles (EVs) containing various biological molecules (cargo), including miRNAs. EVs are not degraded in the gastrointestinal system and circulation; thus, breast milk EVs (bEVs) are expected to interact ...
Young Eun Cho   +10 more
doaj   +1 more source

The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs. [PDF]

open access: yesJournal of Clinical Oncology, 2013
620 Background: Innate or acquired resistance to current HER-targeting drugs indicates that their use for HER2-overexpressing breast cancer (BC) treatment may be compromised. miRNAs may have potential as diagnostic, prognostic and predictive biomarkers for treatment response, as well as therapeutic targets and replacement therapies.
Claire Corcoran   +5 more
openaire   +1 more source

HIV-1 gp120 influences the expression of microRNAs in human monocyte-derived dendritic cells via STAT3 activation [PDF]

open access: yes, 2015
Background: MicroRNAs (miRs) are an abundant class of small non-coding RNAs (~22 nt) that reprogram gene ex- pression by targeting mRNA degradation and translational disruption.
Da Sacco, Letizia   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy